FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP noted that the data submitted by the company showed a small deviation of Mifepristone Linepharma from the acceptable range for bioequivalence with the reference medicine, with Mifepristone Linepharma 200 mg producing slightly higher levels of active substance in the body than Mifegyne 200 mg.
Estonian: Inimravimite komitee märkis, et ettevõtte esitatud andmed näitasid Mifepristone Linepharma ja võrdlusravimi bioekvivalentsust mõneti väljaspool vastuvõetavat vahemikku, sest Mifepristone Linepharma 200 mg tekitas organismis veidi suurema toimeainesisalduse kui Mifegyne 200 mg.
English: The grounds for the referral were that Mifepristone Linepharma had not been shown to be bioequivalent to the reference medicine, Mifegyne 200 mg.
Estonian: Esildise alus oli see, et Mifepristone Linepharma bioekvivalentsus võrdlusravimiga Mifegyne 200 mg ei ole tõendatud.
English: Both medicines are available as 200 mg tablets but whereas Mifegyne was authorised to be given at doses of 600 mg and 200 mg, Mifepristone Linepharma was only authorised at the 200 mg dose.
Estonian: Mifegyne müügiluba on 600 mg ja 200 mg annusele, kuid Mifepristone Linepharma ainus vorm on 200 mg annusega.
English: The final opinion was converted into a Decision by the European Commission on 28 February 2014.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 28. veebruaril 2014.
English: The referral started on 7 November 2012.
Estonian: Esildise menetlemine algas 7. novembril 2012.
English: Written explanations were provided by the applicants and marketing authorisation holders on 15 February 2013 and on 9 September 2013.
Estonian: Müügiloa taotlejad ja hoidjad esitasid kirjalikud selgitused 15. veebruaril 2013 ja 9. septembril 2013.
English: Veterinary Medicines
Estonian: Veterinaarravimite komitee
English: The condition on the marketing authorisations is in Annex IV.
Estonian: Müügilubade tingimused on esitatud IV lisas.
English: International non-proprietary name (INN): enrofloxacin
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): enrofloksatsiin
English: The Committee appointed H. Jukes as rapporteur and E-M. Vestergaard as co-rapporteur.
Estonian: Komitee määras hindajaks H. Jukesi ja kaashindajaks E.-M. Vestergaardi.
English: Enrofloxacin is for veterinary use only.
Estonian: Enrofloksatsiin on ette nähtud ainult veterinaarseks kasutamiseks.
English: The CVMP was requested to consider the indications, dosage regimens and withdrawal periods for chickens and turkeys in order to ensure consumer safety, efficacious treatment in chickens and turkeys, as well as lower the risk of development of antimicrobial resistance to enrofloxacin.
Estonian: Veterinaarravimite komiteel paluti üle vaadata näidustused, annustamine ja keeluajad kanadel ning kalkunitel, et tagada tarbijate ohutus, kanade ja kalkunite efektiivne ravi ning samuti väiksem risk, et haigustekitajatel tekib enrofloksatsiini suhtes resistentsus.
English: Enrofloxacin is a synthetic chemotherapeutic agent from the class of the fluoroquinolone carboxylicacid derivatives.
Estonian: Enrofloksatsiin on sünteetiline kemoterapeutikum, mis kuulub fluorokinolooni karboksüülhappe derivaatide klassi.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amendments in the summaries of product characteristics, labelling and package leaflets in Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning ravimi omaduste kokkuvõtete, pakendi märgistuse ja infolehtede muudatused III lisas.
English: On 18 October 2012, the United Kingdom presented to the Agency a referral notification under Article 35 of Directive 2001/82/EC, regarding all veterinary medicinal products containing enrofloxacin to be administered via the drinking water to chickens and/or turkeys.
Estonian: 28. oktoobril 2012 tegi Ühendkuningriik EMA-le direktiivi 2001/82/EÜ artikli 35 kohase esildise seoses kõigi veterinaarravimitega, mis sisaldavad kanadele ja/või kalkunitele joogiveega manustatavat enrofloksatsiini.
English: It has antibacterial activity against a broad spectrum of Gram-negative and Grampositive bacteria.
Estonian: Enrofloksatsiinil on antibakteriaalne toime paljude gramnegatiivsete ja grampositiivsete bakterite suhtes.
English: Based on the evaluation of the currently available data, the CVMP considered that the overall benefitrisk profile for these products remains positive subject to amendments in the product information and conditions of the marketing authorisations.
Estonian: Olemasolevate andmete hindamise alusel leidis veterinaarravimite komitee, et ravimite üldine kasulikkuse ja riski profiil on jätkuvalt positiivne, kui muudetakse ravimiteavet ja müügilubade tingimusi.
English: Therefore on 7 November 2013 the Committee adopted by consensus a positive opinion, recommending variations to the terms of the marketing authorisations for all veterinary medicinal products containing enrofloxacin to be administered via drinking water to chickens and/or turkeys.
Estonian: Seega võttis komitee 7. novembril 2013 konsensuse alusel vastu positiivse arvamuse, soovitades muuta kõigi veterinaarravimite, mis sisaldavad kanadele ja/või kalkunitele joogiveega manustatavat enrofloksatsiini, müügilubade tingimusi.
English: 28 February 2014
Estonian: EMA/128744/2014
English: 1 bottle, (240 ml)+ 10 ml oral dosing syringe and adapter
Estonian: 240 ml (10 mg/ml) 1 pudel, (240 ml)+ 10 ml suukaudse annustamise süstal ja adapter
English: Oral solution
Estonian: Suukaudne lahus
English: The duration of treatment depends on the patient's condition and response to treatment.
Estonian: Ravi kestus sõltub patsiendi seisundist ja ravivastusest.
English: It is used in patients with:
Estonian: Seda kasutatakse järgmistel patsiendirühmadel:
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zeffix on 29 July 1999.
Estonian: Euroopa Komisjon andis Zeffixi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 29. juulil 1999.
English: The recommended dose of Zeffix is 100 mg once a day.
Estonian: Zeffixi soovitatav annus on 100 mg üks kord ööpäevas.
English: Zeffix lamivudine
Estonian: Zeffix lamivudiin
English: The full EPAR for Zeffix can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zeffixi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Lamivudine stops the virus making DNA and prevents it from multiplying and spreading.
Estonian: Lamivudiin peatab viiruse DNA moodustumise ning takistab selle paljunemist ja levikut.
English: It is available as tablets (100 mg) and an oral solution (5 mg/ml).
Estonian: Seda turustatakse tablettidena (100 mg) ja suukaudse lahusena (5 mg/ml).
English: The CHMP decided that Zeffix's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Zeffixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: In addition, information was presented on the use of Zeffix in patients with decompensated liver disease.
Estonian: Peale selle esitati andmeid Zeffixi kasutamise kohta dekompenseeritud maksahaigusega patsientidel.
English: Zeffix is a medicine that contains the active substance lamivudine.
Estonian: Zeffix on ravim, mis sisaldab toimeainena lamivudiini.
English: For more information about treatment with Zeffix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zeffixiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The most common side effect with Zeffix (seen in more than 1 patient in 10) is raised ALT levels.
Estonian: Zeffixi kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on suurenenud ALT-sisaldus.
English: If the hepatitis B virus can still be found in the blood after six months of treatment, the doctor should consider switching treatment or adding another medicine for hepatitis B to reduce the risk of resistance.
Estonian: Kui kuus kuud kestnud ravi järel on patsiendi veres veel B-hepatiidi viirust, peab arst kaaluma ravi muutmist või muu B-hepatiidi ravimi lisamist, et vähendada resistentsuse tekke riski.
English: This document is a summary of the European public assessment report (EPAR) for Zeffix.
Estonian: See on ravimi Zeffix Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zeffix.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Zeffix was as effective as alfa-interferon.
Estonian: Zeffixi efektiivsus oli sama kui alfainterferoonil.
English: Because the hepatitis B virus can become resistant to Zeffix, the doctor should only consider prescribing Zeffix if other treatments that are less likely to lead to resistance cannot be used;
Estonian: Et B-hepatiidi virus võib muutuda Zeffixi suhtes resistentseks, tuleb arstil määrata Zeffixit ainult juhul, kui muid raviviise, mis tekitavad vähem tõenäoliselt resistentsust, ei saa kasutada;
English: To reduce the risk of resistance, Zeffix must be used in combination with another anti-hepatitis B medicine that does not cause resistance in the same way as Zeffix.
Estonian: Resistentsuse riski vähendamiseks ei tohi Zeffixit kasutada koos muu B-hepatiidi ravimiga, mis tekitab resistentsust teisel viisil kui Zeffix.
English: What is Zeffix?
Estonian: Mis on Zeffix?
English: The other two studies compared Zeffix taken on its own with alfa-interferon (another treatment used in chronic hepatitis B) on its own and with the combination of Zeffix and alfa-interferon.
Estonian: Ülejäänud kahes uuringud võrreldi ainuravimina kasutatud Zeffixit ainuravimina kasutatud alfainterferooniga (samuti kroonilise B-hepatiidi ravim) ning Zeffixi ja alfainterferooni kombinatsiooniga.
English: • compensated liver disease (when the liver is damaged but works normally), who also show signs that the virus is still multiplying and have signs of liver damage (raised levels of the liver enzyme alanine aminotransferase [ALT] and signs of damage when liver tissue is examined under a microscope).
Estonian: • kompenseeritud maksahaigusega patsiendid (maks on kahjustatud, kuid selle talitlus on normaalne), kellel on viiruse edasise paljunemise ning maksakahjustuse nähud (maksaensüümi alaniinaminotransferaasi (ALT) sisalduse suurenemine veres ja maksakoe mikroskoopuuringutel ilmnevad kahjustusnähud).
English: Why has Zeffix been approved?
Estonian: Miks Zeffix heaks kiideti?
English: Other information about Zeffix:
Estonian: Muu teave Zeffixi kohta
English: • decompensated liver disease (when the liver does not work normally).
Estonian: • dekompenseeritud maksahaigusega patsiendid (maksatalitlus on häiritud).
English: Treatment with Zeffix should be started by a doctor who has experience in the management of chronic hepatitis B.
Estonian: Ravi Zeffixiga peab alustama kroonilise B-hepatiidi ravis kogenud arst.
English: Doses lower than 100 mg need to be given using the oral solution.
Estonian: Alla 100 mg annused tuleb anda suukaudse lahusena.
English: These included looking at how the liver damage had evolved after a year of treatment using a liver biopsy (when a small sample of liver tissue is taken and examined under a microscope), as well as measuring other signs of the disease such as the levels of ALT or of hepatitis B virus DNA circulating in the blood.
Estonian: Uuringutes oli mitu efektiivsuse näitajat, näiteks maksakahjustuse areng aasta kestnud ravi ajal (uurides biopsiaga võetud maksakoe proovi mikroskoobiga), samuti muud haigusesümptomid, näiteks ALT- või B-hepatiidi viiruse DNA sisaldus veres.
English: In patients with decompensated liver disease, Zeffix also reduced levels of hepatitis B virus DNA and ALT.
Estonian: Dekompenseeritud maksahaigusega patsientidel vähendas Zeffix B-hepatiidi viiruse DNA ja ALTsisaldust veres.
English: What is the risk associated with Zeffix?
Estonian: Mis riskid Zeffixiga kaasnevad?
English: The active substance in Zeffix, lamivudine, is an antiviral agent that belongs to the class ‘nucleoside analogues'.
Estonian: Zeffixi toimeaine lamivudiin on nukleosiidianaloogide klassi kuuluv viiruseravim.
English: Zeffix is used to treat adults (aged 18 years or over) who have chronic (long-term) hepatitis B (a disease of the liver due to infection with the hepatitis B virus).
Estonian: Zeffixit kasutatakse kroonilise (pikaajalise) B-hepatiidi (B-hepatiidi viiruse nakkusest põhjustatud maksapõletik) raviks täiskasvanutel (vähemalt 18-aastastel).
English: Lamivudine interferes with the action of a viral enzyme called DNA polymerase, which is involved in the formation of viral DNA.
Estonian: Lamivudiin häirib viiruse DNA moodustumisel osaleva viiruseensüümi DNA-polümeraasi aktiivsust.
English: In patients with compensated liver disease, Zeffix was more effective than placebo in slowing down the progression of liver disease.
Estonian: Kompenseeritud maksahaigusega patsientidel aeglustas Zeffix maksahaiguse progresseerumist platseebost efektiivsemini.
English: These are patients infected with hepatitis B virus that has mutated (changed), leading to a form of chronic hepatitis B that is more difficult to treat.
Estonian: (HBeAg-negatiivsed on patsiendid, kes on nakatunud muteerunud (muutunud) viirusega, mille tulemusena on tekkinud raskemini ravitav krooniline B-hepatiidi vorm).
English: About half of the patients taking Zeffix had an improvement in liver damage assessed in a biopsy, compared with about a quarter of the patients who took placebo.
Estonian: Patsientidest, kelle maksakahjustust hinnati biopsia abil, vähenes maksakahjustus Zeffixit saanutest ligikaudu pooltel ja platseebot saanutest ligikaudu veerandil.
English: How does Zeffix work?
Estonian: Kuidas Zeffix toimib?
English: The dose needs to be lower in patients who have reduced kidney function.
Estonian: Neeruprobleemidega patsiendid peavad kasutama väiksemaid annuseid.
English: Zeffix has been studied in five main studies involving a total of 1,083 adults with compensated liver disease due to chronic hepatitis B. Three studies compared Zeffix with placebo (a dummy treatment), one of which looked particularly at ‘HBeAg-negative' patients.
Estonian: Zeffixit uuriti viies põhiuuringus, milles osales kokku 1083 kroonilisest B-hepatiidist tingitud kompenseeritud maksahaigusega täiskasvanud patsienti.
English: For the full list of all side effects or restrictions with Zeffix, see the package leaflet.
Estonian: Zeffixi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefit has Zeffix shown during the studies?
Estonian: Milles seisneb uuringute põhjal Zeffixi kasulikkus?
English: How has Zeffix been studied?
Estonian: Kuidas Zeffixit uuriti?
English: How is Zeffix used?
Estonian: Kuidas Zeffixit kasutatakse?
English: What is Zeffix used for?
Estonian: Milleks Zeffixit kasutatakse?
English: The European Commission granted a marketing authorisation valid throughout the EU for Exforge on 17 January 2007.
Estonian: Euroopa Komisjon andis Exforge müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. Jaanuaril 2007.
English: The full EPAR for Exforge can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Exforge kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Exforge is taken by mouth as one tablet once a day with some water.
Estonian: Exforget võetakse suu kaudu üks tablett üks kord ööpäevas koos vähese veega.
English: Other information about Exforge
Estonian: Muu teave Exforge kohta
English: The CHMP decided that Exforge's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Exforge kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Exforge.
Estonian: See on ravimi Exforge Euroopa avaliku hindamisaruande kokkuvõte.
English: Exforge amlodipine / valsartan
Estonian: Exforge amlodipiin/valsartaan
English: For more information about treatment with Exforge, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Exforgega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effects with Exforge (seen in between 1 and 10 patients in 100) are headache, nasopharyngitis (inflammation of the nose and throat), influenza (flu), hypokalaemia (low blood potassium levels), various types of oedema (swelling), fatigue (tiredness), flushing (reddening), asthenia (weakness) and hot flushes.
Estonian: Exforge kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peavalu, nasofarüngiit (nina-neelupõletik), gripp, hüpokaleemia (vere kaaliumivaegus), mitmesugused tursed, väsimus, nahapunetus, asteenia (nõrkus) ja kuumahood.
English: Exforge is a medicine that contains two active substances, amlodipine and valsartan.
Estonian: Exforge on ravim, mis sisaldab kahte toimeainet, amlodipiini ja valsartaani.
English: What is the risk associated with Exforge?
Estonian: Mis riskid Exforgega kaasnevad?
English: Exforge must not be used in patients who have severe liver or bile problems, patients with certain heart problems and patients with severe hypotension (low blood pressure).
Estonian: Exforget ei tohi kasutada patsiendid, kellel on rasked maksavõi sapiprobleemid, teatud südameprobleemidega patsiendid ega raske hüpotensiooniga (madala vererõhuga) patsiendid.
English: Exforge is used in patients who have essential hypertension (high blood pressure) that is not adequately controlled on either amlodipine or valsartan taken alone.
Estonian: Exforget kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) patsientidel, kelle vererõhku ei saa ainult amlodipiini või valsartaaniga piisavalt reguleerida.
English: The company also presented evidence that the levels of amlodipine and valsartan in the blood were the same in people taking Exforge and people taking the separate medicines.
Estonian: Ettevõte esitas ka andmeid, et amlodipiini ja valsartaani sisaldus veres oli Exforget kasutavatel ning amlodipiini ja valsartaani eraldi kasutavatel patsientidel ühesugune.
English: Why has Exforge been approved?
Estonian: Miks Exforge heaks kiideti?
English: Exforge must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the ‘dihydropyridine derivatives' class, to valsartan, or to any of the other ingredients.
Estonian: Exforget ei tohi kasutada patsiendid, kes on amlodipiini või teiste dihüdropüridiini derivaatide klassi kuuluvate ravimite, valsartaani või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Exforge contains two active substances, amlodipine and valsartan.
Estonian: Exforge sisaldab kahte toimeainet, amlodipiini ja valsartaani.
English: What is Exforge?
Estonian: Mis on Exforge?
English: For the full list of all side effects reported with Exforge, see the package leaflet.
Estonian: Exforge kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How has Exforge been studied?
Estonian: Kuidas Exforget uuriti?
English: How is Exforge used?
Estonian: Kuidas Exforget kasutatakse?
English: What benefit has Exforge shown during the studies?
Estonian: Milles seisneb uuringute põhjal Exforge kasulikkus?
English: The dose of Exforge to be used depends on the doses of amlodipine or valsartan that the patient was taking before.
Estonian: Exforge annus sõltub patsiendi varasemast amlodipiini või valsartaani annusest.
English: What is Exforge used for?
Estonian: Milleks Exforget kasutatakse?
English: Exforge must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Estonian: II tüüpi diabeediga või mõõduka või raske neerupuudulikkusega patsiendid ei tohi kasutada Exforget koos aliskireeni sisaldavate ravimitega (essentsiaalse hüpertensiooni ravimid).
English: The medicine can only be obtained with a prescription.
Estonian: Exforge on retseptiravim.
English: How does Exforge work?
Estonian: Kuidas Exforge toimib?
English: Date of first authorisation: 6 May 2019
Estonian: Müügiloa esmase väljastamise kuupäev: 06. mai 2019
English: Children and adolescents This medicine is only indicated in adults and it is not to be given to children and adolescents.
Estonian: Lapsed ja noorukid See ravim on näidustatud ainult täiskasvanutele ning seda ei tohi anda lastele ega noorukitele.
English: - Take the dose at about the same time each day.
Estonian: - Võtke annus iga päev ligikaudu samal kellaajal.
English: The clinical study report will be submitted by:
Estonian: Kliinilise uuringu raport esitatakse:
English: It is important to take Lorviqua every day, for as long as your doctor asks you to.
Estonian: Oluline on Lorviquat võtta iga päev, nii kaua kui arst on teile öelnud.
English: a Grade categories are based on NCI CTCAE classifications.
Estonian: Raskusastme kategooriad põhinevad NCI CTCAE klassifikatsioonil.
English: The main efficacy results for Study A are included in Tables 3 and 4.
Estonian: Uuringu A efektiivsuse peamised tulemusnäitajad on esitatud tabelites 3 ja 4.
English: Your doctor may investigate further and treat you with other medicines such as antibiotics and steroids.
Estonian: Teie arst võib teha lisauuringud ja ravida teid muude ravimitega, nagu antibiootikumid ja steroidid.
English: Lorviqua with food and drink
Estonian: Lorviqua koos toidu ja joogiga
English: In vitro studies with drug transporters
Estonian: In vitro uuringud ravimite transporteritega
English: These symptoms could be signs of heart problems.
Estonian: Need sümptomid võivad olla südameprobleemide tunnused.
English: Then take the next tablet at the usual time.
Estonian: Seejärel võtke järgmine annus sisse tavapärasel ajal.
English: Delayed or missed doses
Estonian: Hilinenud või vahele jäänud annused
English: Tell your doctor straight away if you notice any of the following side effects (also section 2 What you need to know before you take Lorviqua).
Estonian: Teatage kohe oma arstile, kui te märkate mõnda alljärgnevat kõrvaltoimet (vt ka lõik 2 „Mida on vaja teada enne Lorviqua võtmist“).
English: If you are not able to take the medicine as your doctor has prescribed, or you feel you do not need it anymore, speak with your doctor right away.
Estonian: Kui te ei suuda ravimit võtta arsti poolt määratud viisil või kui te tunnete, et te ei vaja seda enam, siis rääkige kohe oma arstiga.
English: Atrioventricular block occurred in 1.0% of patients.
Estonian: Atrioventrikulaarne blokaad tekkis 1,0% patsientidest.
English: Other medicines and Lorviqua
Estonian: Muud ravimid ja Lorviqua
English: • crizotinib and at least one other ALK TKI.
Estonian: • krisotiniibi ja vähemalt veel ühe teise ALK TKI-ga.
English: You must not take Lorviqua with certain medicines.
Estonian: Lorviquat ei tohi võtta koos teatud ravimitega.